There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in infl ammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD.
INTRODUCTION
Infl ammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, debilitating infl ammatory disorders of the gastrointestinal tract aff ecting adults and children ( 1, 2 ) . A recent systematic review showed rising trends in the incidence and prevalence of IBD worldwide ( 3 ) associated with signifi cant health-care costs amounting to around £470 million in the United Kingdom, up to €5.6 billion annually in Europe, and >$6 billion annually in the United States of America (3) (4) (5) (6) (7) (8) . With an ever expanding therapeutic repertoire, it is important to select patients who may benefi t from early use of immunosuppressants' and/or biological therapies in order to minimize irreversible luminal damage and prevent long-term complications.
Blood-based biomarkers provide a non-invasive estimation of the infl ammatory burden in newly diagnosed IBD. However, relatively few blood-based biomarkers have been extensively validated in IBD, and fewer still are in routine use in the clinic ( 9 ) . Th ere is an emerging interest in discovering novel markers using multiomic platforms that may be valuable in a variety of clinical settings, including IBD diagnostics, disease activity assessments, predicting disease outcomes, and response to therapy (9) (10) (11) .
Th e S100 family of proteins, including S100A8/A9 (calprotectin) and S100A12 (calgranulin), have been implicated in disease pathogenesis and investigated as potential markers of infl ammation ( 12, 13 ) . In IBD, fecal calprotectin (FC) has emerged as a particularly informative tool ( 14 ) . A recent meta-analysis of 13 studies and 1,041 patients found that FC had a pooled sensitivity and specifi city of 0.93 (0.85-0.97) and 0.96 (0.79-0.99), respectively, for IBD and identifi ed those individuals requiring endoscopy for suspected IBD ( 13 ) . Th ere are also data on the role of FC in other clinical settings, such as predicting postoperative CD recurrence and predicting outcomes in acute severe colitis ( 15, 16 ) . However, there are limitations to FC testing in clinical practice. Fecal collection can be a hurdle for patients ( 17 ) and sample delivery and processing delays can hinder its clinical utility. In active UC, FC shows high within-day variability and the optimal timing for sampling is not clear ( 18, 19 ) . A blood-based biomarker such as serum calprotectin (SC) may be more convenient in routine practice and more acceptable to patients. SC has been studied in diseases such as infl ammatory arthropathies and cystic fi brosis (20) (21) (22) (23) (24) . In rheumatoid arthritis, SC was independently predictive of a 10-year radiographic disease progression ( 25 ) , while in cystic fi brosis, SC predicted exacerbation and lung function decline ( 20, 21 ) .
More recently, SC has been investigated in IBD to predict response to and relapse following anti-tumor necrosis factor (anti-TNF) therapy ( 17, 26 ) . In CD patients, SC has a similar profi le to high-sensitivity C-reactive protein (CRP) and compliments FC and high-sensitivity CRP for prediction of relapse aft er anti-TNF withdrawal ( P =0.0173, 0.0024, and 0.0002; hazard ratio (HR): 3.191, 3.561, and 4.120, respectively) ( 17 ) . In murine models, trinitrobenzene sulfonic acid-induced colitis is associated with higher SC levels that correlate closely to macroscopic and microscopic disease scores ( 27 ) . We are yet to understand fully the relationship between SC and the other currently available biomarkers in IBD and the diagnostic and prognostic value of SC in IBD. Our study aims to investigate the role of SC in this clinical setting.
METHODS

Study design
A prospective, single-center case control study was performed in patients with suspected or confi rmed IBD at their fi rst presentation to a tertiary gastrointestinal clinic. Data were collected for patient demographics, including age, sex, age at diagnosis, and date of diagnosis ( Table 1 and Supplementary Table 2 online) . Details of drug therapy and concomitant medications were recorded. Laboratory markers, including CRP and albumin, were measured as part of the research protocol while other routine markers, including hemoglobin, white cell count, platelets, and FC, were recorded within 30 days of recruitment.
Inclusion criteria
Patients with a new diagnosis of IBD were included in the study. Th e Lennard-Jones, Montreal, and Paris criteria were used for diagnosis and classifi cation of clinical phenotypes (28) (29) (30) . Th e control cohort consisted of healthy laboratory volunteers (HC) and patients with gastrointestinal symptoms (symptomatic controls) who had no discernible infl ammatory disease and a diagnosis of functional bowel disease at follow-up ( Supplementary Table 3 ).
Sample collection and processing
For SC analysis, blood samples were collected prospectively and serum was processed within 2 h of sampling (using centrifugation at 2500 g for 15 min) and subsequently stored at −80 °C until further use. Samples were analyzed in duplicate using the Calpro AS calprotectin ELISA (Calpro AS, Lysaker, Norway) according to the manufacturer's instructions. Samples with a calprotectin result of >2500 ng/ml were diluted and retested. Coeffi cients of variation of <10% were included in the analysis.
Ethics statement
Th e NHS Lothian SAHSC Bioresource granted approval for this study (reference number SR558) with all patients giving written and informed consent (15/ES/0094). 
Clinical course in IBD
Case note review was performed for all IBD cases. Treatment escalation was defi ned as the need for escalation and establishment of ≥2 immunomodulatory therapies and/or surgery for disease fl are aft er initial induction of disease remission (criteria previously used by Lee et al. ( 31 ) ). In UC, the defi nition of treatment escalation also included any patient with a new diagnosis, requiring emergency colectomy during their index admission ( Supplementary Table 1 ).
Statistical analysis
Data were analyzed using Microsoft Excel 2010 (Microsoft , Redmond, WA) and R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Continuous data are presented as medians and interquartile ranges (IQRs) and were analyzed using a Mann-Whitney U -test. Categorical data are presented as numbers and percentages and were analyzed using Fisher's exact tests. Spearman's rank-order correlation test was applied for correlations between variables. To determine the accuracy of blood parameter measurements as a prognostic test capable of diagnosing IBD, receiver operating characteristic (ROC) analyses were performed by plotting sensitivity against specifi city using the 'pROC' package in R ( 32 ) .
Building diagnostic and prognostic models
Aft er univariable analyses, the most signifi cant laboratory parameters (CRP, albumin, and SC) were included in multivariable models for IBD diagnosis and prognosis. CRP and SC were log transformed to more closely approximate a normal distribution for further multivariable analysis. ROC analyses were used to defi ne the optimal cut points (highest sum of sensitivity+specifi city) for both models. Th e optimal models were then selected by performing backward stepwise regression using the smallest Akaike information criterion values and adjusted for treatment exposure. For the diagnostic model, an integer score was attributed to each variable according to its relative contribution in the model (as determined by the coeffi cients) and positive and negative predictive values (PPV and NPV, respectively) were then calculated for each total score. For the prognostic model, a Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. Th resholds were then identifi ed using ROC analyses to allow stratifi cation of patients to either a benign or an aggressive disease course (requiring treatment escalation and/or surgery) and to allow creation of survival curves.
RESULTS
Comparison of SC with conventional biomarkers
Overall, SC was analyzed in 171 patient serum samples from August 2013 to April 2015. SC correlated positively with CRP ( ρ =0.61, P =6.9×10 −19 ) and negatively with albumin ( ρ =−0.54, P =3.3×10 −14 ). Paired full blood count was available within 30 days (median 0 days; range: −26 to 16 days) of recruitment in 147 patients. SC correlated positively with neutrophil count ( ρ =0.65, P =1.9×10 −20 ) and negatively with hemoglobin ( ρ =−0.42, P =6.1×10 −8 ). Paired FC was available within 30 days (median 0 days, IQR: −5 to 5 days) of SC in 50 patients (IBD n =31, non-IBD n =19). SC correlated signifi cantly with FC (Spearman's ρ =0.50, P =1.6×10 −4 ). Table 1 summarizes the correlation of blood and fecal parameters. SC demonstrated a stronger correlation with white cell count (William's test, P =0.02) and neutrophils ( P =0.03) in controls compared with IBD cases.
Diagnostic utility of SC in IBD
In a subset of 156 patients (83 IBD and 73 non-IBD), blood sampling was performed within 90 days from diagnosis (median 0 days; IQR 0-6). Th ere were 35 patients with a diagnosis of CD, 45 patients with UC, and 3 patients with IBD unclassifi ed (IBDU) in the IBD group. In CD, 44% had L3 +/− L4 disease and 62% had B1 behavior according to the Montreal classifi cation ( 33 ) . In UC, 33% had pancolitis (E4) and 11% had limited proctitis (E1) as per the Paris classifi cation ( 30 ) . Table 2 and Table 3 summarize the demographics and blood and fecal parameters for the IBD and control cohorts. SC was signifi cantly increased in IBD compared with controls (1,010 ng/ml (IQR 796-1,426 ng/ml) vs. 506 ng/ml (IQR 362-725 ng/ml), P =3.7×10 −15 ; Figure 1 ). CRP and albumin were also signifi cantly diff erent between IBD and controls (CRP P =8.9×10 −15 ; albumin P =4.9×10 −14 ). Th ere was no diff erence in SC between CD and UC (1,015 ng/ml (IQR 740-1,518 ng/ml) vs. 911 μ g/g (IQR 809-1,413 ng/ml), P =0.79) and within controls (HC: 432 ng/ml (IQR 359-586) vs. symptomatic controls: 563 ng/ ml (IQR 382-787); P =0.12). SC was not signifi cantly associated with sex ( P =0.14), age ( ρ −0.06, P =0.43), or smoking status ( P =0.49). SC and CRP were able to discriminate IBD from controls with similar areas under the receiver operator characteristics curve (AUC) of 0.87 (95% confi dence interval (CI) 0.82-0.93) and 0.86 (95% CI 0.80-0.91), respectively ( Figure 2 ; P =0.64 DeLong's test for comparison of ROC curves). In those with paired SC and FC within 30 days, the AUC for discriminating cases and controls was superior for FC (0.99, 95% CI 0.98-1.00) than for SC (0.87, 95% CI 0.78-0.97; P =0.01 De Long's test), as shown in Figure 2 .
Multivariable analysis
Multivariable logistic regression analysis of predictors of IBD was performed on 155 cases (83 IBD, 72 non-IBD) where the data for the predictors were complete. Albumin, male gender, log-transformed CRP, and log-transformed SC were signifi cant predictors of IBD. Table 4 summarizes the statistical signifi cance of each covariate.
Building an IBD diagnosis score
Using the multivariable model, continuous variables were categorized using integer cut points guided by the ROC curves and observed relationship with diagnosis. Th e fi nal scoring system for the diagnosis of IBD included SC>852 ng/ml, Albumin <38 g/l, CRP≥3.5 mg/l, and male gender. To formulate a numerical risk score, each variable was given a score based on the odds ratio (OR) generated from the linear model. Tables 5a and 5b summarize the PPV and NPV for each score. Using this model, a SC> 852 ng/ml and either a CRP≥3.5 mg/l or albumin <38 g/l has INFLAMMATORY BOWEL DISEASE Serum Calprotectin as an IBD Marker a sensitivity of 67%, specifi city of 97%, and a positive likelihood ratio (LR) of 24.14 for IBD.
Predicting disease extent in IBD
SC, CRP, and albumin were not able to diff erentiate between IBD subtypes (CRP P =0.45; albumin P =0.67; SC P =0.49). Within the UC cohort, SC was signifi cantly higher in those with disease beyond the rectum (>E1) compared with proctitis alone (E1) (median SC 1,078 ng/ml IQR 820-1,418 vs. 812 ng/ml IQR 698-821, P =0.03). Albumin also predicted disease extent in UC shown in Table 6a . A score was generated using both biomarkers at these thresholds. At a year, the estimated chance of treatment escalation was 21% (95% CI: 1-37%) if none of the criteria ( P =0.01) but not CRP ( P =0.05). In CD, however, there was no signifi cant diff erence in SC, CRP, or albumin by disease location ( P =0.47, 0.55, and 0.20, respectively).
Predicting disease outcomes in IBD
Kaplan-Meier analyses were performed on a total of 83 patients with IBD. Th ere were 35 patients with a diagnosis of CD, 45 patients with UC, and 3 patients with IBDU. Th e median age was 31 years (IQR: 26-41) and 69% were male ( n =58). A total of 1 (33%), 16 (46%), and 23 (51%) patients required treatment escalation in the IBDU, CD, and UC groups, respectively. Using backwards stepwise selection, albumin <37 g/l and SC ≥1,046 ng/ ml remained signifi cant predictors of treatment escalation in IBD (log-rank test P =5.1×10 −5 ). Both biomarkers had similar HR as 
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were met, 40% (95% CI: 17-56%) for patients meeting one criterion, and 65% (95% CI: 43-78%) for those meeting both criteria ( Figure 3a ) . In order to assess whether the time lag between diagnosis and blood sampling had an impact on the fi nal model, stepwise regression analyses was performed for samples within 60 days ( n =74) and 30 days ( n =60) from diagnosis. SC remained a signifi cant predictor of disease outcomes at 60 and 30 days ( P =0.003 and P =0.004, respectively).
In 28 patients, paired FC was available within 30 days from diagnosis. Using a multivariate model that included age, gender, CRP, albumin, FC, and SC, backward stepwise regression analy- ( a ) Kaplan-Meier survival curves of disease course using blood biomarkers to predict outcomes in newly diagnosed infl ammatory bowel diseases. Single marker represents either albumin <37 g/l or serum calprotectin ≥1046 ng/ml. Dual markers represent a combination of both variables. ( b ) KaplanMeier survival curves of disease course using blood biomarkers to predict outcomes in newly diagnosed Crohn's disease. '1 marker' represents either C-reactive protein (CRP) >24 mg/l or albumin<26 g/l or serum calprotectin >991 ng/ml. '2 or 3 marker' represents a combination of any 2 or 3 of the abovementioned variables. ( c ) Kaplan-Meier survival curves of disease course using blood biomarkers to predict outcomes in newly diagnosed ulcerative colitis. Single marker represents either albumin <37 g/l or CRP >2.5 mg/l. Dual markers represents all the categorical variables as a combined biomarker. For color fi gure, please see full text version. Calprotectin, a member of the S100 proteins, represents 45% of all cytosolic proteins in neutrophils compared with 1% in monocytes ( 34, 35 ) . Given the short half-life of SC (5 h), it may provide a more dynamic test of the current infl ammatory status compared with conventional infl ammatory markers (half-life of CRP 18 h, albumin 19 days) ( 36 ) . SC correlates better with neutrophil count in controls compared with IBD patients; in IBD, SC levels may refl ect calprotectin release from activated neutrophils and other immune cells such as monocytes, macrophages, and epithelial cells ( Figure 4 ). SC shows a strong correlation with other markers such as CRP ( r =0.61, P =6.9×10 −19 ) similar to published studies ( r =0.33-0.59) ( 17, 25, 37, 38 ) and a moderate correlation between SC and FC (0.50, P =1.6×10 −4 ). As a diagnostic blood-based marker, SC is the strongest predictor of IBD 9.37 (95% CI: 2.82-34.68). In a clinical setting, blood markers such as CRP are oft en available, therefore investigating the utility of a combined marker may be more relevant as this allows for greater specifi city in diagnostics ( 39, 40 ) . We generated an IBD scoring system that would allow clinicians to predict IBD in patients at their index clinical visit. If 2 blood marker criteria are met (score of ≥8), there is a high likelihood of IBD (positive LR 24.14).
FC has a high NPV but a low PPV for IBD vs. functional disease (cutoff 50 μ g/g, NPV 93%, PPV 37%) ( 41 ) . In practice, a blood biomarker model can complement the existing FC screening of sis was performed and only SC remained as a signifi cant predictor ( P =0.0004). FC did not predict disease outcomes in this cohort ( P =0.85, HR=1.0).
Further regression analyses were performed within the subgroups UC ( Table 6b ) and CD ( Table 6c ). In CD, CRP>24 mg/l and SC>991 ng/ml and albumin <26 g/l predicted treatment escalation (log-rank test P =0.003). At 1 year, the estimated chance of treatment escalation was 11% (95% CI: 0-29%) for patients meeting none of the criteria, 30% (95% CI: 0-51%) for patients meeting one criterion, and 80% (95% CI: 31-94%) for patients meeting two or more criteria ( Figure 3b ).
In UC, albumin <37 g/l and CRP>2.5 g/l predicted a more aggressive disease course (log-rank test P =0.001). At 1 year, the estimated chance of treatment escalation was 0 for patients meeting none of the criteria, 38% (95% CI: 0-61%) for patients meeting one criterion, and 68% (95% CI: 41-83%) for patients meeting two criteria ( Figure 3c ).
DISCUSSION
Th ere is an unmet need for accurate diagnostic and prognostic biomarkers in IBD as currently available blood biomarkers lack sensitivity and/or specifi city. Our study is the fi rst to investigate 
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Serum Calprotectin as an IBD Marker patients with gastrointestinal symptoms in primary care. In the current climate of optimal tertiary care resource management, this model can be utilized for patients being referred for suspected IBD and help select and prioritize investigations for individuals with a high IBD score and a high likelihood of disease. Th e AUC for FC is superior to SC in our study (0.87 and 0.99, respectively, P =0.01). FC has an established role in IBD diagnostics; however, in clinical practice fecal sampling and testing can be challenging. One consideration in interpreting these data is the lag between SC and FC testing. Th e median time lag between SC and FC testing was 0 days (IQR −5 to 5 days), but there were individuals with upto 30 days between SC and FC testing. Nonetheless, any time lag represents real-life experience with fecal testing as oft en FC is not available until a few weeks aft er the clinic visit. Th ere is a large variability in the concentration of FC in stool within a single day and storage conditions can impact on FC levels ( 18 ) . Sampling feces can be a hurdle for patients and individuals can decline FC testing, fail to provide a sample, or provide insuffi cient sample for analysis. Th ese factors impact on the practical utility of FC. SC testing has the potential to provide a more timely assessment of infl ammation on the day of the visit. Th e cost per sample for performing SC testing are comparable to FC (£5; $7.3 equivalent). In addition, other costs related to sample handling and processing are likely to be lower as serum testing is oft en automated.
Beyond diagnostics, studies have investigated the utility of noninvasive markers in predicting endoscopic activity. A recent metaanalyses evaluated the diagnostic accuracy of CRP, FC, and stool lactoferrin for the assessment of endoscopically defi ned activity in IBD. Th e pooled AUC for CRP, FC, and stool lactoferrin were 0.49 (95% CI: 0.34-0.64), 0.88 (CI: 0.84-0.90), and 0.73 (CI: 0.66-0.79) ( 42 ) . Th ere was, however, heterogeneity in the endoscopic index used. Other factors such as inclusion criteria, in particular time lag between blood/fecal sampling and endoscopy (0-7 days), diff ered (43) (44) (45) (46) . Th ere is a need for future prospective studies investigating the performance of non-invasive endoscopic activity markers, such as SC.
In our study, SC predicts treatment escalation and/or surgery in IBD (HR 2.7, 95% CI: 1.1-4.9), in particular CD (HR 4.2, 95% CI 1.2-15.3). We also generate blood-based prognostic models incorporating CRP, albumin, and SC. At 1 year, our model can predict treatment escalation in IBD in 65% of cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) in CD if ≥2 criteria are met. Predicting the disease course early in individuals is becoming increasingly important in order to identify patients who would benefi t from more aggressive therapy. In clinical practice, there is an unmet need for early indicators of persistent activity, either in a continuous or in a relapsing-remitting manner despite initial induction therapy ( 31 ) . Th ese patients will oft en go on to require further immunomodulators, biological therapies, and/or surgery. As quiescent IBD do not require such treatment escalations, we used the requirement of such treatment escalations to defi ne an aggressive disease course ( 31 ) . Clinical predictors have been studied previously. In CD, Beaugerie et al. ( 47 ) identifi ed age, the presence of perianal disease, and requirement for steroids at diagnosis as independent predictive factors for a disabling course. However, biological markers were not analyzed in that study. Since then, the role of biomarkers in predicting the disease course has been the focus of many studies, although their eff ectiveness in predicting outcomes vary ( 31, (48) (49) (50) (51) . Most studies suggest that CRP predicts relapse in IBD (48) (49) (50) , although one study found that it had no predictive value ( 52 ) . Th ere are several reasons for this observed variation and includes diff erences in defi ning an aggressive disease course, disease heterogeneity, and disease duration prior to analyses. It is also possible that variations in CRP genotype may explain variations in its performance in adult cohort studies. Th is has been described in the pediatric population ( 53 ) , but yet to be explored in adults. Th e role of FC in predicting colectomy in acute severe colitis has been investigated previously (AUC 0.65, P =0.04), and more recently, SC has been shown to predict colectomy in acute severe colitis with an AUC of 0.69 (95% CI 0.53-0.81) compared with FC (AUC 0.58; 95% CI 0.35-0.81) and CRP (AUC 0.71; 95% CI: 0.56-0.86) ( 16, 38 ) . SC has also been studied as a prognostic marker in predicting relapse aft er anti-TNF withdrawal and complements FC (>250 μ g/g) and high-sensitivity CRP (>5 mg/l) ( P =0.0173, 0.0024, and 0.0002; HR: 3.191, 3.561, and 4.120, respectively) ( 17 ). Our study, however, is the fi rst to explore the prognostic utility of SC at diagnosis. Future studies incorporating periodic SC testing to predict disease course in IBD may be useful.
Our study does have certain limitations. Th e results are from a single tertiary center and based on a select cohort of newly diagnosed IBD patients. Th e relatively small numbers within the subtype of IBD limits the power to dissect factors predicting phenotype and our diagnostic and prognostic models require further validation. Th ere were more females with functional bowel disease in the control cohort and this alone may underly the observation that male gender is a risk factor for IBD in our study. Th e major strengths of this study include a prospective design and a cohort of newly diagnosed IBD aiming for the fi rst time to explore the correlation of SC with current biomarkers and build diagnostic and prognostic models for potential clinical use in IBD.
SC shows promise as a blood-based biomarker in diagnosing and predicting disease course in IBD. A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the infl ammatory burden in IBD and has the potential to predict disease and its outcomes. Our fi ndings warrant further exploration and validation within large multicenter cohorts.
